Key Highlights
•
A 12-month follow-up of the DISTAL trial found that endovascular treatment plus best medical treatment did not reduce disability or death in patients with medium or distal vessel occlusion stroke compared to best medical treatment alone. These findings reinforce the 90-day results and argue against the routine use of endovascular treatment for mild-to-moderate medium or distal vessel occlusion stroke.
Source →
•
Researchers developed a digital seed amplification assay (dSAA) that can precisely quantify TDP-43 protein aggregates in cerebrospinal fluid, finding elevated seeds in patients with frontotemporal lobar dementia that correlated with disease severity. This single-aggregate resolution technology provides a technical foundation for a sensitive diagnostic and monitoring tool for TDP-43-related neurodegenerative diseases.
Source →
•
A new study provides appropriate use recommendations for the amyloid-targeting antibody lecanemab in UK clinical practice, over a year after its regulatory approval for Alzheimer’s disease. The recommendations highlight practical and organizational challenges that must be addressed to integrate this new class of disease-modifying therapy into routine care.
Source →
•
The CORRECT-BD trial compared right unilateral ultrabrief electroconvulsive therapy (ECT) to magnetic seizure therapy (MST) for bipolar depression, reporting both clinical and cognitive outcomes. This head-to-head comparison provides important data on the relative benefits and cognitive side effects of these two brain stimulation treatments for a challenging mood disorder.
Source →
•
This article discusses the use of computational phenotyping to analyze effort-based decision-making in people with type-2 diabetes, both while taking semaglutide and after stopping the medication. The work provides insight into how a widely used diabetes and weight-loss drug may influence motivation and reward-related behavior.
Source →
Stay curious. Stay informed —
Science Briefing
